Hemoglobinopathies Clinical Trial
Official title:
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
This is a treatment guideline for a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) in patients with non-malignant or malignant diseases. This regimen, consisting of busulfan, fludarabine, and low dose total body irradiation (TBI), is designed to promote engraftment in patients who failed to achieve an acceptable level of donor-derived engraftment following a previous allogeneic HCT.
There is no research element except the collection of routine clinical data. Patients will consent to allow routine clinical data to be collected and maintained in OnCore, the Masonic Cancer Center's (MCC) clinical database, and specific transplant related endpoints in the University Of Minnesota Blood and Bone Marrow Database as part of the historical database maintained by the department. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00034528 -
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
|
Phase 2 | |
| Active, not recruiting |
NCT03655678 -
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia
|
Phase 2/Phase 3 | |
| Completed |
NCT03609827 -
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
| Recruiting |
NCT06107400 -
Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease
|
Early Phase 1 | |
| Enrolling by invitation |
NCT02986698 -
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)
|
Phase 1 | |
| Completed |
NCT00744692 -
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
|
Phase 1 | |
| Recruiting |
NCT05799118 -
Study of the Role of Genetic Modifiers in Hemoglobinopathies
|
||
| Active, not recruiting |
NCT03745287 -
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT00673608 -
Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
|
Phase 4 | |
| Recruiting |
NCT04644016 -
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
|
Phase 2 | |
| Recruiting |
NCT04853576 -
A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05356195 -
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
|
Phase 3 | |
| Completed |
NCT03609840 -
Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
| Active, not recruiting |
NCT01850108 -
Non-Myeloablative Conditioning and Bone Marrow Transplantation
|
N/A | |
| Recruiting |
NCT05329649 -
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
|
Phase 3 | |
| Active, not recruiting |
NCT01966367 -
CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Completed |
NCT00153985 -
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
|
Phase 2 | |
| Recruiting |
NCT03128996 -
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
|
Phase 1/Phase 2 | |
| Completed |
NCT03149289 -
Hepatitis C Virus Infection in Patients With Hemoglobinopathies
|
N/A | |
| Completed |
NCT00000588 -
Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone
|
Phase 2 |